BioCentury | Dec 19, 2005
Strategy

Abgenix chronicles

Abgenix chronicles Selected events tracked against Abgenix's weekly market cap since it went public in July 1998. Mcap in $M (log scale) 6/24/96 - Spins out of Cell Genesys (CEGE) and raises $10M in a series...
BioCentury | May 23, 2005
Finance

Ebb & Flow

This year's American Society of Clinical Oncology conference saw muted moves compared with the run up in the months preceding last year's conference and the hosing that cancer companies received during and after last year's...
BC Extra | Aug 3, 2004
Top Story

Cephalon meets Street

CEPH reported second quarter EPS of $0.39, meeting the Street estimate and up 30% from $0.30 in the second quarter last year. CEPH's earnings exclude a $30.1 million impairment charge associated with a write-off of...
BC Week In Review | Jun 7, 2004
Company News

MDS supply/service, proteomics news

MDS subsidiary MDS Proteomics discontinued its drug discovery and development business to focus on providing services in biomarker identification, lead optimization and proteomics. MDS Proteomics will provide biomarkers it discovers to MDS, which will use...
BC Week In Review | Jan 20, 2003
Company News

MDS, Eli Lilly deal

MDS subsidiary MDS Proteomics partnered with Eli Lilly Canada Inc. (Toronto, Ontario) to research the use of MDS's PhosMap proteomics technology in LLY's kinase inhibitor program. MDS Inc. (TSE:MDS; MDZ), Toronto, Ontario   Eli Lilly...
BC Week In Review | Jan 13, 2003
Company News

Cephalon, MDS deal

CEPH will use MDS subsidiary MDS Proteomics Inc.’s differential analysis, chemiproteomics, PhosMap phosphorylation fingerprinting and protein interaction mapping technologies in its small molecule development programs for central nervous system diseases. Under the five-year deal, CEPH...
BC Extra | Jan 7, 2003
Company News

Cephalon, MDS Proteomics deal

CEPH will use technology from MDS Proteomics , a subsidiary of MDS (TSE:MDS; MDZ), to aid in expanding potential indications for CEPH compounds, enhancing its chemical library and identifying CNS targets. CEPH will use MDS's differential...
BC Week In Review | Mar 4, 2002
Company News

MDS Proteomics other research news

Researchers published in Nature Biotechnology a methodology for analyzing phosphoproteins from a whole cell lysate in a single experiment using mass spectrometry. The method was applied to a whole cell lysate of S. cerevisiae, and...
BioCentury | Feb 25, 2002
Finance

Bells & whistles

". . . never send to know for whom the bell tolls; it tolls for thee." - John Donne, Meditation XVII It was as predictable as the sun rising in the east that the excesses of 2000 would...
BC Week In Review | Feb 11, 2002
Company News

MDS Proteomics, Kazusa DNA Research Institute deal

MDS acquired the institute’s collection of 2,000 disease-related, full-length cDNA clones. MDS will use the clones for mapping disease pathways and determining protein function. MDS Proteomics Inc. , (TSE:MDS; MDZ), Toronto, Ontario   Kazusa DNA Research...
Items per page:
1 - 10 of 39
BioCentury | Dec 19, 2005
Strategy

Abgenix chronicles

Abgenix chronicles Selected events tracked against Abgenix's weekly market cap since it went public in July 1998. Mcap in $M (log scale) 6/24/96 - Spins out of Cell Genesys (CEGE) and raises $10M in a series...
BioCentury | May 23, 2005
Finance

Ebb & Flow

This year's American Society of Clinical Oncology conference saw muted moves compared with the run up in the months preceding last year's conference and the hosing that cancer companies received during and after last year's...
BC Extra | Aug 3, 2004
Top Story

Cephalon meets Street

CEPH reported second quarter EPS of $0.39, meeting the Street estimate and up 30% from $0.30 in the second quarter last year. CEPH's earnings exclude a $30.1 million impairment charge associated with a write-off of...
BC Week In Review | Jun 7, 2004
Company News

MDS supply/service, proteomics news

MDS subsidiary MDS Proteomics discontinued its drug discovery and development business to focus on providing services in biomarker identification, lead optimization and proteomics. MDS Proteomics will provide biomarkers it discovers to MDS, which will use...
BC Week In Review | Jan 20, 2003
Company News

MDS, Eli Lilly deal

MDS subsidiary MDS Proteomics partnered with Eli Lilly Canada Inc. (Toronto, Ontario) to research the use of MDS's PhosMap proteomics technology in LLY's kinase inhibitor program. MDS Inc. (TSE:MDS; MDZ), Toronto, Ontario   Eli Lilly...
BC Week In Review | Jan 13, 2003
Company News

Cephalon, MDS deal

CEPH will use MDS subsidiary MDS Proteomics Inc.’s differential analysis, chemiproteomics, PhosMap phosphorylation fingerprinting and protein interaction mapping technologies in its small molecule development programs for central nervous system diseases. Under the five-year deal, CEPH...
BC Extra | Jan 7, 2003
Company News

Cephalon, MDS Proteomics deal

CEPH will use technology from MDS Proteomics , a subsidiary of MDS (TSE:MDS; MDZ), to aid in expanding potential indications for CEPH compounds, enhancing its chemical library and identifying CNS targets. CEPH will use MDS's differential...
BC Week In Review | Mar 4, 2002
Company News

MDS Proteomics other research news

Researchers published in Nature Biotechnology a methodology for analyzing phosphoproteins from a whole cell lysate in a single experiment using mass spectrometry. The method was applied to a whole cell lysate of S. cerevisiae, and...
BioCentury | Feb 25, 2002
Finance

Bells & whistles

". . . never send to know for whom the bell tolls; it tolls for thee." - John Donne, Meditation XVII It was as predictable as the sun rising in the east that the excesses of 2000 would...
BC Week In Review | Feb 11, 2002
Company News

MDS Proteomics, Kazusa DNA Research Institute deal

MDS acquired the institute’s collection of 2,000 disease-related, full-length cDNA clones. MDS will use the clones for mapping disease pathways and determining protein function. MDS Proteomics Inc. , (TSE:MDS; MDZ), Toronto, Ontario   Kazusa DNA Research...
Items per page:
1 - 10 of 39